https://go.evvnt.com/77755-3 Sheraton Commander Hotel
16 Garden St
Cambridge, MA 02138
$Gold - conference & 2 workshops: $3897, Silver - conference & 1 workshop: $3298, Conferennce only: $2699, Individual workshops: $699
Focussed on Non-Alcoholic Steatohepatitis, this inaugural Summit will bring together drug developers to solve the challenges they face from drug discovery to late stage clinical development.
Across 3 jam-packed days the brightest minds from the likes of Genentech, Bristol-Myers Squibb, Avolynt, Pfizer and many more will converge at this summit to discuss the data, insight and lessons learned enabling you to:
-Optimize recapitulation of human NASH in vivo and effectively translate into the clinic
- Validate non-invasive biomarker approaches and technologies to more robustly diagnose and track disease progression
- Improve drug efficacy in both early and late stage NASH by identifying and validating novel targets & drug mechanisms of action
- Define clinical primary and secondary endpoints and road-map your regulatory path to approval
Join your peers in Cambridge, MA, to overcome the challenges that are preventing you from accelerating the development of your NASH candidate.
Speakers: Raffi Werner, Weilin Xie, Sophie Mégnien, Manu Chakravarthy, Anthony Azzara, James Trevaskis, Kendra K. Bence, Stephen Previs, Melissa Palmer, Robert Arch, Steven England, Bill Wilkison, Reshma Shringarpure, Jesper Gromada, Ajit Dash, Laurent Fischer, Dean Hum, David Lomb, Rachel Beckerman, David Q.-H. Wang, Keld Fosgerau